外科理论与实践

外科理论与实践 >

2020 , Vol. 25 >Issue 02: 155 - 158

DOI: https://doi.org/10.16139/j.1007-9610.2020.02.014

综述

肠道菌群作为结肠直肠癌生物标志物及其干预的临床意义

展开
  • 同济大学附属第十人民医院肠道微生态诊疗中心 同济大学医学院肠道疾病研究所,上海 200072

收稿日期: 2010-03-09

  网络出版日期: 2020-04-25

收起

Clinical significance of gut microbiota in colorectal cancer: biomarker and intervention

Expand

Received date: 2010-03-09

  Online published: 2020-04-25

Fold

本文引用格式

张雪莹, 秦环龙 . 肠道菌群作为结肠直肠癌生物标志物及其干预的临床意义[J]. 外科理论与实践, 2020 , 25(02) : 155 -158 . DOI: 10.16139/j.1007-9610.2020.02.014

参考文献

[1] Xie YH, Gao QY, Cai GX, et al. Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies[J]. EBio Medicine, 2017, 25:32-40.
[2] Saus E, Iraola-Guzmán S, Willis JR, et al. Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential[J]. Mol Aspects Med, 2019, 69:93-106.
[3] Mizutani S, Yamada T, Yachida S. Significance of the gut microbiome in multistep colorectal carcinogenesis[J]. Cancer Sci, 2020, 111(3):766-773.
[4] Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium[J]. Nat Rev Microbiol, 2019, 17(3):156-166.
[5] Hamada T, Zhang X, Mima K, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status[J]. Cancer Immunol Res, 2018, 6(11):1327-1336.
[6] Pleguezuelos-Manzano C, Puschhof J, Huber AR, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli[J]. Nature, 2020-02-27.[Epub ahead of print]
[7] Palmgren Colov E, Helene Degett T, Raskov H, et al. The impact of the gut microbiota on prognosis after surgery for colorectal cancer - a systematic review and meta-analysis[J]. APMIS, 2020-02-04.[Epub ahead of print]
[8] Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population[J]. J Gastroenterol, 2018, 53(4):517-524.
[9] Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3):548-563,e16.
[10] Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism[J]. Oncotarget, 2016, 7(29):46158-46172.
[11] Selby K, Levine EH, Doan C, et al. Effect of sex, age, and positivity threshold on fecal immunochemical test accuracy: a systematic review and meta-analysis[J]. Gastroenterology, 2019, 157(6):1494-1505.
[12] Bosch LJW, Melotte V, Mongera S, et al. Multitarget stool DNA test performance in an average-risk colorectal cancer screening population[J]. Am J Gastroenterol, 2019, 114(12):1909-1918.
[13] Zhang X, Zhu X, Cao Y, et al. Fecal fusobacterium nucleatum for the diagnosis of colorectal tumor: A systema-tic review and meta-analysis[J]. Cancer Med, 2019, 8(2):480-491.
[14] Guo S, Li L, Xu B, et al. A simple and novel fecal biomarker for colorectal cancer: ratio of fusobacterium nucleatum to probiotics populations, based on their antagonistic effect[J]. Clin Chem, 2018, 64(9):1327-1337.
[15] Yang J, Li D, Yang Z, et al. Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families[J]. Gut Microbes, 2020-01-23.[Epub ahead of print]
[16] Coker OO, Nakatsu G, Dai RZ, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer[J]. Gut, 2019, 68(4):654-662.
[17] Nakatsu G, Zhou H, Wu WKK, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes[J]. Gastroenterology, 2018, 155(2):529-541,e5.
[18] Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer[J]. Clin Cancer Res, 2017, 23(8):2061-2070.
[19] Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer[J]. Gut, 2017, 66(1):70-78.
[20] Thomas AM, Manghi P, Asnicar F, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation[J]. Nat Med, 2019, 25(4):667-678.
[21] Zhang J, Haines C, Watson AJM, et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study[J]. Gut, 2019, 68(11):1971-1978.
[22] Ou J, Carbonero F, Zoetendal EG, et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans[J]. Am J Clin Nutr, 2013, 98(1):111-120.
[23] Mehta RS, Nishihara R, Cao Y, et al. Association of die-tary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue[J]. JAMA Oncol, 2017, 3(7):921-927.
[24] Cruz BCS, Sarandy MM, Messias AC, et al. Preclinical and clinical relevance of probiotics and synbiotics in co-lorectal carcinogenesis: a systematic review[J]. Nutr Rev, 2020,pii:nuz087.
[25] Chang CW, Liu CY, Lee HC, et al. Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluo-rouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model[J]. Front Microbiol, 2018, 9:983.
[26] Wang ZH, Liu JM, Li CY, et al. Bacterial biofilm bioinspired persistent luminescence nanoparticles with gut-oriented drug delivery for colorectal cancer imaging and chemotherapy[J]. ACS Appl Mater Interfaces, 2019, 11(40):36409-36419.
[27] Zheng DW, Dong X, Pan P, et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy[J]. Nat Biomed Eng, 2019, 3(9):717-728.
[28] Darbandi A, Mirshekar M, Shariati A, et al. The effects of probiotics on reducing the colorectal cancer surgery complications: A periodic review during 2007-2017[J]. Clin Nutr, 2019,pii: S0261-5614(19)33135-33138.
[29] Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies[J]. Science, 2018, 359(6382):1366-1370.
[30] Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018, 24(12):1804-1808.
[31] Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis[J]. Gut, 2016, 65(12):1973-1980.
Options
文章导航

/

〈 〉